Freeline Therapeutics Stock

freeline.lifeHealthcare / BioTech & PharmaFounded: 2015Funding to Date: $205.53MM

Freeline is a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases.

Register To Buy and Sell Shares

For more details on financing and valuation for Freeline Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Freeline Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Freeline Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Brian Silver JD
Chief Financial Officer & Head of Corporate Development
Karen Law
Natalia Misciattelli
Senior Vice President, Strategy and Business Operations
Markus Horer Ph.D
Co-Founder, Chief Technology Officer & Managing Director
Jane Whitrow Ph.D
Vice President, Finance & Company Secretary
Jan Thirkettle Ph.D
Chief Development Officer
Amit Nathwani
Co-Founder, Chief Scientific Officer & Board Member
Gerard Short
Senior Vice President, Head of Clinical and Regulatory
Romuald Corbau Ph.D
Vice President, Research

Board Members

Christopher Hollowood Ph.D
Amit Nathwani
Martin Andrews
Jeffrey Chodakewitz MD
Updated on: Dec 8, 2023


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.